FUTURE OF HEALTHCARE
Athlete | September 27, 2022
Whether for active adults or Olympians, Athlete Training and Health (ATH) encourages its athletes to strive for their own personal best. ATH is raising its own bar on community health and performance training once again, with the announcement of two new facilities in the Houston area and the addition of another world-renowned coach to its executive staff.
“What we know is that evidence-led training allows everyone to benefit from the science behind the best in health and performance. Expanding and offering this world-class environment and approach will benefit athletes of all ages and abilities. We are pleased to collaborate with healthcare systems, professional sports teams, universities and school districts to continue pursuing a new level of health and performance training for many communities.”
Greg Centilli, chief operating officer for ATH and a recent addition to the growing ATH organization
Construction has begun on a new ATH sports medicine and human performance facility in Pearland. Located on the Memorial Hermann Pearland Hospital campus at 16100 South Freeway, the roughly 13K-square-foot facility will house unparalleled human performance expertise and opportunities to train in an adult fitness space, a professional sport-style weight room, and on indoor and outdoor turf fields. The facility, a collaboration between ATH, Memorial Hermann and UT Physicians Orthopedics, is expected to open fall 2023.
Also in the works is an ATH facility in Cypress, also in collaboration with Memorial Hermann. On the campus of Memorial Hermann Cypress Hospital at 27800 Highway 290, ATH will open and operate a roughly 13K-square-foot facility in 2024. At this location, student, collegiate, professional and adult athletes will find the expertise needed to up their game on their own performance.
“We are extremely pleased to welcome Professor Cronin to ATH. His science-based expertise and educational experience, alongside his international standing, will help educate investors and the general markets on the significance and industry importance of ATH-led initiatives,” said Centilli.
Cronin serves as professor of strength and conditioning at the Sports Performance Research Institute of New Zealand (SPRINZ) at Auckland University of Technology (AUT). His research interests are in human movement, particularly around strengthening of muscle, injury resistance, return to play and high-performance sports. Cronin’s research has been published in more than 400 peer-reviewed papers.
AUT and ATH have a long-standing history. Post-graduate fellows from AUT conduct research at ATH as part of a team involving coaches and select students, as well as collaborate on sport technology development.
“I know the organization well, and my research interests and expertise align well with ATH’s interest in sporting performance and allied health, so I’m very excited to be advising ATH about the latest science-based studies and learnings to support their people, programs and products,” Cronin said.
While its clients celebrate personal victories, ATH celebrates industry wins. Readers of Living Magazine recently voted ATH the “2022 Best Health Club/Gym” winner in McKinney/Allen and in Katy/Fulshear via an annual award competition that allows readers to nominate and then vote for their favorite companies by category and market.
ATH also was honored to be named a “2022 Neighborhood Favorite” in NextDoor’s annual celebration of local businesses, and a finalist for “2022 Best Gym/Fitness Center in Houston” by readers of Houston Chronicle in an annual awards competition voted on by Houstonians.
“While it’s important for us to acknowledge the hard work of our coaches and staff who make awards like these possible, it’s our job to continuously raise the bar, so we consider this just the beginning,” noted Centilli. “We are excited about what we have accomplished and are even more excited for the developments ahead.”
Whether it’s losing the pandemic pounds, living in a healthier body, or even reaching the pinnacle of your sport, the certified, experienced sports performance experts at ATH have the expertise and a program tailored just for you.
ABOUT ATHLETE TRAINING AND HEALTH (ATH)
ATH is more than a gym. It’s a place of community, inspiration and results. ATH provides award-winning adult fitness and sports performance training for youth, collegiate and professional athletes. ATH utilizes best practices from human performance research to provide a world-class training environment for athletes and adults of all fitness levels collaborating with hospitals, professional sports teams, universities and school districts to set new standards for health and performance training. ATH invests heavily in the post-graduate education of its performance coaches, who in turn develop evidence-led training programs guaranteed to deliver sustainable results. ATH currently operates two training centers in the Houston metro area and one in Allen, north of DFW.
Signify Health | September 26, 2022
Signify Health a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare networks to create and power value-based payment programs, has again achieved the National Committee for Quality Assurance certification for the Healthcare Effectiveness Data and Information Set. This is the second year in which the Company has received this certification.
NCQA provides accreditations and certifications to evaluate a wide range of organizations across the healthcare system. More than 90 percent of health plans in the United States, covering 190 million people, rely on NCQA’s HEDIS measurement tool.
The methodology that Signify Health uses to identify Medicare members who have gaps in their care and would benefit from in-home diagnostic testing was evaluated and certified by NCQA. Receiving this certification allows Signify Health to provide services that align with the industry's most rigorous data assessment processes, resulting in more accurate and timely clinical services for eligible members.
“Through our comprehensive data set and analytics, Signify Health is able to effectively identify at-risk patients and connect them with the appropriate diagnostic and preventive services. We are proud to once again have achieved this NCQA certification, demonstrating our ability to effectively identify gaps in care and to support access to high-quality health services.”
Marc Rothman, MD, Chief Medical Officer, Signify Health
NCQA HEDIS measures relate to many of the most significant chronic health conditions facing seniors in Medicare. In 2021, Signify Health announced the certifications for diabetes care, kidney health evaluation in patients with diabetes, colorectal cancer screening, and osteoporosis management in women.
In 2022, Signify Health was recertified for all of the measures from 2021 that are still recognized by NCQA and expanded its certification to include osteoporosis screening as a preventive measure for older women who have not had a fracture. Osteoporosis is a serious bone disease that impacts the quality of life, especially for women aged 67-85. With the appropriate screenings and interventions, the risk of future bone fractures related to osteoporosis can be reduced.
HEDIS® is a registered trademark of the National Committee for Quality Assurance. NCQA Measure Certification Program™ is a trademark of the National Committee for Quality Assurance.
About Signify Health
Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to build trusted relationships to make people healthier. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home.
NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set is the most widely used performance measurement tool in health care.
Tivic Health | October 18, 2022
Tivic Health® Systems, Inc. a commercial-phase health technology company focused on bioelectronic medicine, announced it has entered into a definitive agreement to acquire the Reliefband product line for nausea treatment and all related assets from Reliefband Technologies, LLC.
Reliefband has been an innovator in wearable, FDA-cleared electronic therapeutics for treatment of nausea and vomiting. Reliefband has multiple products available both over-the-counter and by prescription.
“We are incredibly excited to add the full suite of Reliefband products to our commercial portfolio. The Reliefband team successfully pioneered a direct-to-consumer business model for medical products. This acquisition, when combined with our growing direct-to-consumer sales of ClearUP, will significantly accelerate Tivic’s revenue opportunities.”
Jennifer Ernst, CEO of Tivic Health
Recurring nausea impacts approximately 1 in 6 US adults. According to QY Research, nausea treatment is a $2.4B market in the US and $5.5B globally, growing at 6.5% CAGR.
Reliefband’s wrist-worn electronic nerve stimulators have been FDA-cleared for treatment of nausea associated with seven independent clinical indications, including nausea from motion sickness, pregnancy, migraines, anxiety, chemotherapy, various medications and hangovers.
The patented products are backed by 40 peer-reviewed clinical studies and have generated over 3500 Amazon reviews averaging 4+ stars.
Both Reliefband and ClearUP products offer consumers ways to manage health-related conditions without the issues and side effects often associated with medication use. Both are FDA-cleared, highly effective, fast-acting, convenient, and drug-free. Both currently are sold primarily online, and both have received CE Marks allowing international expansion.
In addition to the Reliefband direct-to-consumer branded products, Tivic will also acquire Reliefband’s Reletex-branded prescription nausea treatments. Reletex products are currently distributed by hospitals and medical professionals and are reimbursed under HCPCS code E0765 for certain conditions.
“We look forward to growing Tivic with the addition of clinically proven, revenue-producing bioelectronic products that have seen strong customer adoption and growth,” continued Ernst.
Consideration to be provided by Tivic consists of up to $33.5 million, of which up to $1.5 million can be paid, at the election of Tivic, in restricted common stock of Tivic. Consideration is subject to working capital adjustments, less Reliefband transaction expenses and any indebtedness of Reliefband at closing.
The transaction is expected to be consummated in the fourth quarter of 2022 or first quarter of 2023 after the satisfaction of certain customary closing conditions, including but not limited to securing the financing necessary to pay the purchase price. Additional information on the transaction can be found in a Current Report on Form 8-K filed by Tivic with the Securities and Exchange Commission (SEC).
Johnson & Johnson | September 21, 2022
Johnson & Johnson opened its San Francisco Bay Campus, a state-of-the-art Research & Development facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the Company into the Bay Area innovation ecosystem to strengthen and increase collaborations with innovators to accelerate growth.
“Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions. On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.”
Joaquin Duato, Chief Executive Officer, Johnson & Johnson
The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies, novel treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning. Co-locating expertise at the site will enable the expansion of the Company’s world-class discovery engine and industry-leading pipeline.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” said James Merson, Ph.D., Site Head, San Francisco Bay Campus and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC.
The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystem since 2014. The San Francisco Bay Campus, along with the Company’s JLABS @ South San Francisco, will continue to enable the Company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the Company will increase its focus on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health.
Building on Johnson & Johnson’s long-standing commitment to use its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, reinforcing the Company’s pledge to be responsible stewards in creating a healthy, more sustainable future. The aim is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the most widely used green building rating system in the world.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health.
About Johnson & Johnson Technology
Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from any location, our digital tools infuse our products with novelty, dexterity, and ease.